{"id":"https://openalex.org/W3211967262","doi":"https://doi.org/10.1182/blood-2021-148352","title":"Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma","display_name":"Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma","publication_year":2021,"publication_date":"2021-11-05","ids":{"openalex":"https://openalex.org/W3211967262","doi":"https://doi.org/10.1182/blood-2021-148352","mag":"3211967262"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2021-148352","doi":"https://doi.org/10.1182/blood-2021-148352","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-148352","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069406522","display_name":"Steven M. Horwitz","orcid":"https://orcid.org/0000-0002-6399-2006","observed_orcids":["https://orcid.org/0000-0002-6399-2006"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven M. Horwitz","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013717203","display_name":"Tatyana A. Feldman","orcid":"https://orcid.org/0000-0002-4458-2896","observed_orcids":["https://orcid.org/0000-0002-4458-2896"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tatyana A. Feldman","raw_affiliation_strings":["John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ","institution_ids":["https://openalex.org/I1324520350"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059475389","display_name":"Jing C. Ye","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jing C. Ye","raw_affiliation_strings":["University of Michigan, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Michigan, Ann Arbor, MI","institution_ids":["https://openalex.org/I27837315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057879662","display_name":"Michael Siavash Khodadoust","orcid":"https://orcid.org/0000-0001-9061-7351","observed_orcids":["https://orcid.org/0000-0001-9061-7351"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael S. Khodadoust","raw_affiliation_strings":["Stanford University School of Medicine, Palo Alto, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University School of Medicine, Palo Alto, CA","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090442154","display_name":"Javier L Munoz","orcid":"https://orcid.org/0000-0002-9060-8911","observed_orcids":["https://orcid.org/0000-0002-9060-8911"]},"institutions":[{"id":"https://openalex.org/I4387154023","display_name":"Banner MD Anderson Cancer Center","ror":"https://ror.org/049c9q337","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I2802412784","https://openalex.org/I4387154023"]}],"countries":[],"is_corresponding":false,"raw_author_name":"Javier Munoz","raw_affiliation_strings":["Banner MD Anderson Cancer Center, Gilbert, AZ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Banner MD Anderson Cancer Center, Gilbert, AZ","institution_ids":["https://openalex.org/I4387154023"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012810450","display_name":"Paul A. Hamlin","orcid":"https://orcid.org/0000-0001-9500-1804","observed_orcids":["https://orcid.org/0000-0001-9500-1804"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul A. Hamlin","raw_affiliation_strings":["Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103275168","display_name":"Youn H. Kim","orcid":"https://orcid.org/0000-0003-2686-5873","observed_orcids":["https://orcid.org/0000-0003-2686-5873"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Youn H. Kim","raw_affiliation_strings":["Stanford University School of Medicine, Palo Alto, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University School of Medicine, Palo Alto, CA","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020537159","display_name":"Ryan A. Wilcox","orcid":"https://orcid.org/0000-0002-6420-0760","observed_orcids":["https://orcid.org/0000-0002-6420-0760"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan A. Wilcox","raw_affiliation_strings":["University of Michigan, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Michigan, Ann Arbor, MI","institution_ids":["https://openalex.org/I27837315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005718112","display_name":"Manish R. Patel","orcid":"https://orcid.org/0000-0001-6836-2364","observed_orcids":["https://orcid.org/0000-0001-6836-2364"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Manish R. Patel","raw_affiliation_strings":["Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110303299","display_name":"Greg Coffey","orcid":"https://orcid.org/0009-0008-2566-3755","observed_orcids":["https://orcid.org/0009-0008-2566-3755"]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Greg P. Coffey","raw_affiliation_strings":["Alexion, AstraZeneca Rare Disease, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion, AstraZeneca Rare Disease, Boston, MA","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011323071","display_name":"Muhtarjan Osman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Muhtarjan Osman","raw_affiliation_strings":["Alexion, AstraZeneca Rare Disease, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion, AstraZeneca Rare Disease, Boston, MA","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065729832","display_name":"Jaymes S. Holland","orcid":"https://orcid.org/0009-0004-0532-1740","observed_orcids":["https://orcid.org/0009-0004-0532-1740"]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jaymes S Holland","raw_affiliation_strings":["Alexion, AstraZeneca Rare Disease, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion, AstraZeneca Rare Disease, Boston, MA","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074347500","display_name":"Cristina B. Guzm\u00e1n","orcid":"https://orcid.org/0000-0002-8500-9463","observed_orcids":["https://orcid.org/0000-0002-8500-9463"]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cristina B Guzman","raw_affiliation_strings":["Alexion, AstraZeneca Rare Disease, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion, AstraZeneca Rare Disease, Boston, MA","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005159945","display_name":"Sonali M. Smith","orcid":"https://orcid.org/0000-0002-9893-4949","observed_orcids":["https://orcid.org/0000-0002-9893-4949"]},"institutions":[{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sonali M. Smith","raw_affiliation_strings":["The University of Chicago Medical Center, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago Medical Center, Chicago, IL","institution_ids":["https://openalex.org/I4210087865"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"138","issue":"Supplement 1","first_page":"622","last_page":"622"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/peripheral-t-cell-lymphoma","display_name":"peripheral T-cell lymphoma","score":0.9100000262260437},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.949999988079071},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.7580000162124634},{"id":"https://openalex.org/keywords/angioimmunoblastic-t-cell-lymphoma","display_name":"angioimmunoblastic T-cell lymphoma","score":0.9039999842643738},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.7020000219345093},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.902999997138977},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.3179999887943268},{"id":"https://openalex.org/keywords/cd30","display_name":"CD30","score":0.4129999876022339},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.3790000081062317},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase","display_name":"Bruton's tyrosine kinase","score":0.6029999852180481}],"concepts":[{"id":"https://openalex.org/C35174551","wikidata":"https://www.wikidata.org/wiki/Q7660502","display_name":"Syk","level":4,"score":0.7470609545707703},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6969985961914062},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5924637317657471},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.528852105140686},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5266641974449158},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5020034313201904},{"id":"https://openalex.org/C2777891184","wikidata":"https://www.wikidata.org/wiki/Q7168693","display_name":"Peripheral T-cell lymphoma","level":4,"score":0.4683372974395752},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4272543787956238},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3225168287754059},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2866629958152771},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.1937142312526703},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.17134049534797668},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.16331222653388977},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.1576855480670929},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.13233652710914612},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.10041007399559021},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2021-148352","doi":"https://doi.org/10.1182/blood-2021-148352","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-148352","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.6000000238418579,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W87517608","https://openalex.org/W3032246833","https://openalex.org/W2412306442","https://openalex.org/W2065582169","https://openalex.org/W2937428028","https://openalex.org/W2352815992","https://openalex.org/W1992594661","https://openalex.org/W2594642741","https://openalex.org/W2412435376","https://openalex.org/W2006193743"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Peripheral":[2],"T-cell":[3,11,207,266,283],"lymphoma":[4],"(PTCL)":[5],"comprises":[6],"a":[7,66,575,580,825,866],"heterogeneous":[8],"group":[9],"of":[10,52,60,74,168,204,217,227,390,412,572,592,603,780,908,920,935,958,971,988,1001,1014,1031,1046,1066,1080,1093,1122,1160,1191,1213],"non-Hodgkin's":[12],"lymphomas":[13,286],"with":[14,76,106,294,386,408,499,551,600],"poor":[15],"prognosis":[16],"that":[17],"are":[18,33],"often":[19],"refractory":[20,250,563],"to":[21,164,251,401,444,564,623],"treatment.":[22,567],"Spleen":[23],"tyrosine":[24],"kinase":[25,29],"(SYK)":[26],"and":[27,58,101,121,171,206,229,280,285,357,435,455,485,491,496,530,538,544,574,652,811,848,862],"Janus":[28],"(JAK)":[30],"signaling":[31],"pathways":[32],"important":[34],"tumor":[35],"survival":[36,173],"mechanisms":[37],"in":[38,65,93,138,180,190,220,232,346,489,510,514,541,549,585,597,608],"PTCL.":[39,542,587],"Cerdulatinib":[40,534],"(ALXN2075)":[41],"is":[42,418],"an":[43,122,777,905,917,932,955,968,985,998,1011,1028,1043,1063,1077,1090,1119,1157,1188,1210],"orally":[44],"active,":[45],"small":[46],"molecule,":[47],"reversible":[48],"ATP-competitive":[49],"dual":[50,582],"inhibitor":[51,584],"SYK/JAK":[53,583],"family":[54],"members.":[55],"The":[56,147,459],"efficacy":[57,300],"safety":[59,348],"cerdulatinib":[61,133,228,593],"monotherapy":[62],"were":[63,97,175,209,230,264,297,472,493,504,547,562,612],"investigated":[64],"multicenter,":[67],"single-arm":[68],"Phase":[69],"2a":[70],"dose-expansion":[71],"study":[72,213],"(NCT01994382)":[73],"patients":[75,92,181,192,200,219,255,293,427,446,512,550,556],"T-":[77],"or":[78,144,782,910,922,937,960,973,990,1003,1016,1033,1048,1068,1082,1095,1124,1162,1193,1215],"B-cell":[79],"malignancies;":[80],"we":[81],"report":[82],"the":[83,87,94,221,310,327,347,396,515,552,589,601,604,618],"final":[84],"results":[85],"from":[86],"PTCL":[88,95,105,222,273,312,354,433,516,605],"cohort.":[89],"Methods":[90],"Eligible":[91],"cohort":[96,223,313],"aged":[98],"\u226518":[99],"years":[100],"had":[102,183,257,558],"histologically":[103],"confirmed":[104],"relapsed/refractory":[107,586],"disease":[108,142,324,470],"after":[109],"\u22651":[110,184,195,225],"prior":[111,245,258,451],"systemic":[112],"therapy":[113,452],"(prior":[114],"brentuximab":[115],"was":[116,150,178,188,304,332,350,368,382,399,428],"required":[117],"for":[118,299,309,353,360,366,380,395,425,432,439,507,579,620],"CD30+":[119],"patients)":[120],"Eastern":[123],"Cooperative":[124],"Oncology":[125],"Group":[126],"performance":[127],"status":[128],"\u22641.":[129],"Patients":[130],"received":[131,194,224],"oral":[132],"30":[134],"mg":[135],"twice":[136],"daily":[137],"28-day":[139],"cycles":[140],"until":[141],"progression":[143],"unacceptable":[145],"toxicity.":[146],"primary":[148,505],"endpoint":[149],"investigator-assessed":[151],"overall":[152,311,355,434],"response":[153,165,169],"rate":[154],"(ORR)":[155],"based":[156],"on":[157,423,448,776,904,916,931,954,967,984,997,1010,1027,1042,1062,1076,1089,1118,1156,1187,1209],"Lugano":[158],"criteria.":[159],"Secondary":[160],"endpoints,":[161],"including":[162,555],"time":[163,422,445],"(TTR),":[166],"duration":[167],"(DoR),":[170],"progression-free":[172],"(PFS),":[174],"estimated.":[176],"Efficacy":[177],"evaluated":[179,189],"who":[182,193,557],"post-baseline":[185],"scan.":[186],"Safety":[187],"all":[191,426],"dose.":[196],"Results":[197],"Overall,":[198],"220":[199],"(with":[201],"various":[202],"subtypes":[203],"B-":[205],"malignancies)":[208],"enrolled":[210],"across":[211],"6":[212,511],"cohorts.":[214],"A":[215],"total":[216],"65":[218,240,292],"dose":[226],"included":[231],"this":[233,598],"analysis:":[234],"63.1%":[235],"male;":[236],"median":[237,243,387,403,409],"(range)":[238,244,364,378,388,404,410,421],"age":[239],"(21-85)":[241],"years;":[242],"regimens":[246],"2":[247,375],"(1-10);":[248],"49.2%":[249],"last":[252,450,566],"treatment;":[253],"18":[254],"(27.7%)":[256],"stem":[259],"cell":[260],"transplant.":[261],"Histologic":[262],"types":[263],"angioimmunoblastic":[265],"lymphoma/T":[267],"follicular":[268],"helper":[269],"(AITL/TFH":[270],"[N=29;":[271],"44.6%]);":[272],"not":[274,497],"otherwise":[275],"specified":[276],"(NOS":[277],"[N=11;":[278],"16.9%]);":[279],"other":[281],"rare":[282],"leukemias":[284],"(N=25;":[287],"38.5%;":[288],"Table":[289],"1).":[290,302],"Of":[291],"PTCL,":[295],"58":[296],"evaluable":[298],"(Table":[301],"ORR":[303,331,343],"36.2%":[305],"(95%":[306,334,344],"CI":[307,335],"24.0-49.9%)":[308],"(12":[314],"complete":[315],"responses":[316,320,546,611],"[CRs];":[317],"9":[318],"partial":[319],"[PRs];":[321],"14":[322],"stable":[323],"[SD]).":[325],"For":[326],"AITL/TFH":[328,361,367,381,397,553],"subgroup":[329,398],"(N=27),":[330],"51.9%":[333],"31.9-71.3%)":[336],"(10":[337],"CR;":[338],"4":[339],"PR;":[340],"3":[341],"SD).":[342],"CI)":[345],"population":[349,517],"32.3%":[351],"(21.2-45.1%)":[352],"(N=65)":[356],"48.3%":[358],"(29.4-67.5%)":[359],"(N=29).":[362],"Median":[363,377,420],"TTR":[365],"1.9":[369],"(1.5-16.5)":[370],"months":[371,385,407,431,438],"(first":[372],"scan":[373],"at":[374],"months).":[376],"DoR":[379],"12.9":[383],"(0.0-35.5)":[384],"follow-up":[389,411],"16.4":[391],"(0-35.5)":[392],"months.":[393,415],"PFS":[394],"estimated":[400],"be":[402],"4.6":[405],"(0.6-37.4)":[406,414],"22.4":[413],"Further":[416],"assessment":[417],"warranted.":[419],"treatment":[424,508,594],"2.9":[429],"(0.2-37.9)":[430],"3.3":[436],"(0.5-37.9)":[437],"AITL/TFH,":[440],"which":[441],"appears":[442,595],"comparable":[443],"spent":[447],"their":[449,565],"(median":[453],"2.2":[454],"3.0":[456],"months,":[457],"respectively).":[458],"most":[460],"common":[461],"(\u22655%)":[462],"grade":[463],"\u22653":[464],"treatment-emergent":[465],"adverse":[466],"events":[467,503],"(TEAEs),":[468],"excluding":[469],"progression,":[471],"increased":[473,478],"amylase":[474,490],"(23.1%),":[475],"anemia":[476],"(20.0%),":[477],"lipase":[479,492],"(18.5%),":[480],"neutropenia":[481],"(12.3%),":[482],"sepsis":[483],"(9.2%),":[484],"diarrhea":[486],"(7.7%).":[487],"Increases":[488],"transient,":[494],"reversible,":[495],"associated":[498],"clinical":[500,539],"pancreatitis.":[501],"Adverse":[502],"reasons":[506],"discontinuation":[509],"(9.2%)":[513],"(2":[518],"EBV":[519],"reactivation,":[520],"1":[521,526,528,531,628],"West":[522],"Nile":[523],"viral":[524],"infection,":[525,529],"sepsis,":[527],"colitis).":[532],"Conclusions":[533],"demonstrated":[535],"acceptable":[536],"tolerability":[537],"activity":[540,616],"Complete":[543],"durable":[545],"observed":[548],"subtype,":[554],"repeatedly":[559],"relapsed":[560],"and/or":[561],"These":[568],"data":[569],"provide":[570],"proof":[571],"concept":[573],"promising":[576],"efficacy/safety":[577],"profile":[578,591],"first-in-class,":[581],"Overall":[588],"benefit/risk":[590],"favorable":[596],"population,":[599],"exception":[602],"NOS":[606],"subgroup,":[607],"whom":[609],"no":[610],"seen.":[613],"This":[614],"subtype-specific":[615],"raises":[617],"potential":[619],"biomarker":[621],"identification":[622],"optimize":[624],"patient":[625],"selection.":[626],"Figure":[627,629],"1.":[630],"Disclosures":[631],"Horwitz:":[632],"ADC":[633,666,845],"Therapeutics,":[634,651,667,673,682,793,846],"Affimed,":[635,665],"Aileron,":[636],"Celgene,":[637,674,802],"Daiichi":[638,704,1150],"Sankyo,":[639],"Forty":[640,708],"Seven,":[641,709],"Inc.,":[642],"Kyowa":[643,678,716,834,857,1022],"Hakko":[644,679,717],"Kirin,":[645,680,835,858],"Millennium":[646],"/Takeda,":[647],"Seattle":[648,685,731,808,1085],"Genetics,":[649,686,809],"Trillium":[650,691,745],"Verastem/SecuraBio.:":[653],"Consultancy,":[654,719,733,747,850,928,952,994,1007,1024,1059,1074,1087],"Research":[655,658,661,695,702,706,711,720,723,734,748,753,796,813,886,898,925,940,943,946,949,963,976,979,1020,1036,1071,1098,1101,1113,1127,1131,1134,1138,1142,1145,1148,1152,1167,1171,1175,1179,1183,1196,1199,1202,1205,1218,1222],"Funding;":[656,659,662,696,703,707,712,721,724,735,749,814,887,899,926,941,944,947,950,964,977,980,1021,1037,1072,1099,1114,1128,1132,1135,1139,1143,1146,1149,1153,1168,1172,1176,1180,1184,1197,1200,1203,1206,1219,1223],"Affimed:":[657],"Aileron:":[660],"Acrotech":[663],"Biopharma,":[664],"Astex,":[668],"Merck,":[669,803],"Portola":[670,893],"Pharma,":[671,801],"C4":[672,697],"Janssen,":[675,810,829,883],"Kura":[676,713],"Oncology,":[677,855],"Myeloid":[681,725,773],"ONO":[683,728],"Pharmaceuticals,":[684],"Shoreline":[687,739],"Biosciences,":[688,740],"Inc,":[689],"Takeda,":[690],"Th:":[692],"Consultancy;":[693,699,715,727,730,738,742,744,751],"Celgene:":[694,902,1185],"Therapeutics:":[698,701,726,746,774,795,1137,1141,1166,1170,1174,1221],"Crispr":[700],"Sankyo:":[705,1151],"Inc.:":[710,741],"Oncology:":[714],"Kirin:":[718,1023],"Millennium/Takeda:":[722],"Pharmaceuticals:":[729],"Genetics:":[732,1086],"Secura":[736,1038],"Bio:":[737,1039],"Takeda:":[743,1073],"Tubulis:":[750],"Verastem/Securabio:":[752],"Funding.":[754,797,1102],"Feldman:":[755],"Alexion,":[756,765,785,815,836,888,1051,1104],"AstraZeneca":[757,766,786,816,889,1052,1105],"Rare":[758,767,787,817,890,1053,1106],"Disease:":[759,768,788,818,1054,1107],"Honoraria,":[760,929,982,995,1008,1025,1040,1060],"Other:":[761,769,789,819,851,895,1055,1108],"Study":[762,770,790,820,896,1056,1109],"investigator.":[763,771,1110],"Ye:":[764],"Khodadoust:":[772],"Membership":[775,903,915,930,953,966,983,996,1009,1026,1041,1061,1075,1088,1117,1155,1186,1208],"entity's":[778,906,918,933,956,969,986,999,1012,1029,1044,1064,1078,1091,1120,1158,1189,1211],"Board":[779,907,919,934,957,970,987,1000,1013,1030,1045,1065,1079,1092,1121,1159,1190,1212],"Directors":[781,909,921,936,959,972,989,1002,1015,1032,1047,1067,1081,1094,1123,1161,1192,1214],"advisory":[783,852,911,923,938,961,974,991,1004,1017,1034,1049,1069,1083,1096,1125,1163,1194,1216],"committees;":[784,992,1005,1018,1050,1084,1164],"investigator;":[791,821,1057],"CRISPR":[792],"Nutcracker":[794],"Munoz:":[798],"Bayer,":[799,823,870],"Gilead/Kite":[800],"Portola,":[804],"Incyte,":[805,882],"Genentech,":[806],"Pharmacyclics,":[807],"Millennium:":[812],"Pharmacyclics/Abbvie,":[822],"Kite,":[824,838,865,900],"Gilead":[826,867],"Company,":[827,868],"Pfizer,":[828],"Juno/Celgene,":[830],"Bristol":[831],"Myers":[832],"Squibb,":[833],"Fosun":[837],"Innovent,":[839],"Seagen,":[840,872],"BeiGene,":[841],"Debiopharm,":[842],"Epizyme,":[843],"Karyopharm,":[844,901],"Servier,":[847],"Genmab:":[849],"role;":[853],"Targeted":[854],"OncView,":[856],"Physicians'":[859],"Education":[860],"Resource,":[861],"Seagen:":[863],"Honoraria;":[864],"Kyowa,":[869],"Pharmacyclics/Janssen,":[871],"Acrotech/Aurobindo,":[873],"Beigene,":[874],"Verastem,":[875],"AstraZeneca,":[876],"Celgene/BMS,":[877],"Genentech/Roche.:":[878],"Speakers":[879],"Bureau.":[880],"Hamlin:":[881],"Molecular":[884],"Templates:":[885],"Disease":[891],"(formerly":[892],"Pharmaceuticals):":[894],"investigator,":[897],"committees.":[912],"Kim:":[913],"Portola:":[914],"committees,":[924,939,962,975,1035,1070,1097,1126,1195,1217],"Galderma:":[927],"Elorac:":[942],"Soligenix:":[945],"Eisai:":[948],"Innate:":[951],"Corvus:":[965],"Trillium:":[978],"Mundipharma:":[981],"Sanofi:":[993],"Regeneron:":[1006],"CRISPR:":[1019],"Merck:":[1058],"Horizon:":[1100],"Wilcox:":[1103],"Patel:":[1111],"ModernaTX:":[1112],"EMD":[1115],"Serono:":[1116],"Evelo":[1129],"Biosciences:":[1130],"GlaxoSmithKline:":[1133],"Bicycle":[1136],"Mirati":[1140],"Vigeo:":[1144],"Incyte:":[1147],"Pharmacyclics:":[1154],"Checkpoint":[1165],"Effector":[1169],"Forma":[1173],"H3":[1177],"Biomedicine:":[1178],"Boehringer":[1181],"Ingelheim:":[1182],"Agenus:":[1198],"Ignyta:":[1201],"Jacobio:":[1204],"Janssen:":[1207],"Jounce":[1220],"Klus":[1224],"Pharma:":[1225],"Resear":[1226]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}